Study about efficacy of Dexmedetomidine as a novel sedative agent during ESD for esophageal cancer
Phase 2
- Conditions
- Esophageal cancer (SCC)
- Registration Number
- JPRN-UMIN000017302
- Lead Sponsor
- Department of Gastroenterology,Cancer Institute Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
Not provided
Exclusion Criteria
1 Uncontrollable hypertention 2 Uncontrollable heart disease or arrhythmia 3 Respiratory disease needed oxygen in rest 4 Unstable angina (newly occurred or worsened in these 3 weeks) or myocardial infarction within 6 months 5 Difficult to discontinue antithrombotic drugs during preoperative period 6 Severe infectious disease needed systemic treatment 7 Patients judged inappropriate by investigator or attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method